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Kidney immune cell infiltration and oxidative stress contribute
to prenatally programmed hypertension.
Background. Prenatal environment has been shown to mod-
ify adult blood pressure profile, but the underlying mechanisms
are not well understood. The role of renal immune cell infil-
tration, oxidative stress, and nitric oxide bioavailability in the
pathogenesis was investigated.
Methods. Adult hypertension in rat offspring was induced
by maternal low protein diet. Oxidative stress was determined
by quantitative immunoblotting for nitrotyrosine, and T-cell
and macrophage content by immunostaining, in offspring kid-
neys before and after the onset of hypertension. Nitric oxide
metabolites (NOx) were measured in 24-hour urines. A group
of offspring was treated with the immunosuppressive drug my-
cophenolate mofetil (MMF) to reduce inflammation, or with
the superoxide dismutase mimetic Tempol to reduce oxidative
stress, for a 3-week period before the onset of hypertension.
Results. During the prehypertensive stage, at 4 weeks of age,
the low protein diet pups exhibited an increase in kidney nitroty-
rosine content and in number of immune cells, both of which
persisted in untreated animals after hypertension was estab-
lished, at 8 weeks of age. Urine NOx was increased at 4 weeks
and unchanged at 8 weeks of age. Both MMF and Tempol treat-
ment prevented the immune cell infiltration, the increase in
kidney nitrotyrosine abundance, and the development of hy-
pertension. The effect on blood pressure persisted throughout
the 4- to 10-week observation period after discontinuation of
the treatments.
Conclusion. Renal oxidative stress and infiltrating immune
cells may play a pathogenetic role in prenatally programmed
hypertension. Nitric oxide bioavailability does not appear
impaired.
The concept of “prenatal programming” has evolved
over the past decade and half to indicate modulation of
future adult phenotype by nongenetic environmental fac-
tors in utero. After the initial observations of Barker et al
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[1] on the association of low birth weight with later risk
of cardiovascular morbidity, programming of hyperten-
sion has become the most extensively studied example
of prenatal programming. Both epidemiologic data [2–
5] and experimental studies [6–13] have provided strong
evidence that prenatal environment contributes to adult
blood pressure profile. In humans, malnutrition during
pregnancy is associated with increased risk of essential
hypertension in the offspring [2]. In experimental ani-
mals, maternal protein [6–10] and calorie [11] restriction
as well as maternal glucocorticoid treatment [12, 13] have
been used to program adult hypertension in the offspring.
Although other mechanisms have been postulated, ev-
idence is accumulating that the kidney plays a key role
in the development of prenatally programmed hyperten-
sion. Similar to human essential hypertension [14], and
to some experimental models of hypertension [15, 16],
the total number of nephrons is decreased in prenatally
programmed hypertension [9, 10, 17, 18]. Therefore, re-
duced glomerular filtration rate (GFR) may play a role
in the pathogenesis by impairing sodium and fluid bal-
ance regulation [19, 20]. In addition, we have reported up-
regulation of renal sodium transport proteins, suggesting
that increased renal sodium reabsorption may contribute
to sodium retention [21].
Prenatal programming of hypertension is also associ-
ated with abnormalities in the renin-angiotensin system
(RAS) within the kidney [10, 22, 23]. Activation of RAS
may be linked to tissue oxidative stress [24–26], and re-
cent studies have strongly suggested that oxidative stress
in the kidney plays a pathogenetic role in several types of
experimental hypertension (for review, see [27]), possi-
bly by causing relative intrarenal deficiency of nitric oxide
[28, 29].
The current study was based on the hypothesis that re-
nal inflammation, oxidative stress, and resulting decrease
in nitric oxide bioavailability in the kidney are important
mediators of prenatally programmed hypertension. A rat
model of prenatally programmed hypertension, induced
by maternal low protein diet during the last 9 days of ges-
tation, was used to explore these potential mechanisms.
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In our model, the rat offspring become hypertensive be-
tween 6 and 8 weeks of life [8, 9]; to avoid confounding
secondary consequences of hypertension, we therefore
focused on two time points, one immediately preceding
the onset of hypertension, age 4 weeks, and the second
soon after hypertension was established, at 8 weeks. The
results strongly suggest that immune cell infiltration and
oxidative stress in the kidney are important in the patho-
genesis, but the findings are not consistent with decreased
nitric oxide bioavailability.
METHODS
Sprague-Dawley rats (Harlan, Indianapolis, IN, USA)
were used for all experiments. The study protocol was ap-
proved by the Institutional Animal Care and Use Com-
mittees of the Research Institute for Children and LSU
Health Sciences Center. Timed-pregnant rats arrived at
our facility on day 10 of pregnancy and were housed in
temperature-controlled 12-hour light/dark environment.
After a 48-hour acclimatization period they were placed
on low protein diet (6% protein by weight) (Purina Mills
Test Diets, Richmond, VA, USA) to induce prenatally
programmed hypertension in the offspring as previously
described [8, 9]. The dams were allowed to deliver. There
were no significant differences in litter sizes between
the low protein and control pregnancies. No premature
deliveries or immediate postnatal abnormalities in the
pups were observed. The birth weights of the pups from
protein-restricted pregnancies were approximately 15%
lower than those from normal pregnancies, consistent
with our previous observations [8, 9]. All litters were re-
duced to 8 to 10 pups after birth. All dams were on stan-
dard 20% protein diet after delivery and were allowed
to nurse their own offspring until weaning at 21 days of
age. The offspring in each experimental subgroup (de-
scribed below) were derived from at least four different
litters and consisted of approximately equal number of
males and females. Three separate series of studies were
performed:
Series 1: Untreated offspring
Kidneys from extra pups from low protein pregnan-
cies and control pregnancies were harvested on day 1 of
life for protein isolation. The remaining offspring were
followed on standard rat chow without pharmacologic or
other interventions. Equal number of males and females
were killed at 4 weeks of age, which is the time period
immediately preceding the onset of hypertension in our
model, and at 8 weeks of age, after hypertension was es-
tablished [8, 9].
Series 2: Mycophenolate mofetil (MMF) treatment
Offspring from control and low protein diet pregnan-
cies were randomly assigned at 21 days of age to either
vehicle or MMF treatment, resulting in four experimental
groups: (1) control-vehicle, (2) control-MMF, (3) low pro-
tein diet-vehicle, and (4) low protein diet-MMF. The im-
munosuppressive drug MMF (Roche Laboratories Inc.,
Nutley, NJ, USA) was suspended in water (6 mg/mL) im-
mediately prior to administration and given in a dose of
30 mg/kg/day. Pilot experiments with varying doses of
MMF were performed to confirm that this dose was tol-
erated without obvious side effects as described by others
[30]. MMF and vehicle (water) were given daily by gas-
tric gavage. The treatments were continued for 3 weeks,
from age 21 days to age 42 days. A subgroup of animals
from each experimental group was killed at 8 weeks of
age and the remainder were followed for blood pressure
monitoring until 10 weeks of age.
Series 3: Tempol treatment
Low protein diet pups were randomized at 21 days
of age to either no treatment (low protein diet) or to
treatment with the superoxide dismutase mimetic Tempol
(low protein diet-Tempol). The control group consisted of
untreated pups from normal pregnancies. Tempol (Sigma
Chemical Co., St. Louis, MO, USA) was given in drink-
ing water in a concentration of 0.34 g/L for a period of
3 weeks, until 42 days of age. This dose has been shown
to be effective in reducing oxidative stress and to be well
tolerated in rats [31]. A subgroup from each experimental
group was killed at 8 weeks of age. The remainder were
monitored until 16 weeks of age.
All pups were allowed standard chow and water ad libi-
tum after weaning. Before sacrifice, 24-hour urines were
collected from the animals killed at 4 or 8 weeks of age
for determination of urine nitrate + nitrite (NOx) ex-
cretion. Euthanasia was performed using intraperitoneal
pentobarbital, 100 mg/kg. Blood was collected from the
abdominal aorta before the heart stopped. One kidney
was removed for protein isolation, the other kidney for
morphologic studies.
As an index of nitric oxide production, total nitrite
was determined in 24-hour urine collections after conver-
sion of nitrate to nitrite by the enzyme nitrate reductase.
Nitrite was then measured by the Griess method using
a commercial kit (Total Nitric Oxide Assay) (R&D Sys-
tems Inc., Minneapolis, MN, USA).
Kidney nitrotyrosine content was determined in whole
kidneys by quantitative immunoblotting as previously de-
scribed [21]. Briefly, for total protein isolation, one kid-
ney was cut into small pieces, homogenized in ice-cold
isolation solution of 250 mmol/L sucrose, 10 mmol/L tri-
ethanolamine, 1 lg/mL leupeptin, and 0.1 mg/mL phenyl-
methylsulfonyl fluoride (PMSF), centrifuged, and the
pellet discarded. Final protein concentration was ad-
justed to 2 lg/mL and the samples were solubilized in
Laemmli sample buffer. Importantly, an initial preloading
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sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis (SDS-PAGE), stained with Coomassie Blue, was
done for each set of samples to confirm equal loading
among samples [21]. After subsequent SDS-PAGE on
10% polyacrylamide gels, the bands were transferred
electrophoretically to polyvinylidine difluoride (PVDF)
membranes, blocked with 5% milk, probed overnight
at 4◦C with rabbit antinitrotyrosine antibody (Upstate
Biotechnologies, Charlottesville, VA, USA) and then
incubated with secondary antibody (goat antirabbit
IgG) (Pierce Biotechnology, Rockford, IL, USA). The
bands were visualized by chemiluminescence (SuperSig-
nal West Dura Extended Duration Substrate) (Pierce
Biothechnology) and exposed to Versa Doc Imaging Sys-
tem (Bio-Rad Laboratories, Hercules, CA, USA). One
major band, approximately 66 kD was detected along
with three or four faint bands, consistent with the pres-
ence of several nitrolysated protein species [24, 32]. The
major band was analyzed by Quantity One software (Bio-
Rad Laboratories). The readings of low protein diet sam-
ples were normalized to those of control samples run on
the same gel.
T-cell and macrophage infiltration was determined in
4 lm thick paraffin-embedded kidney sections. Mon-
oclonal anti-CD3 antibody (BD Biosciences Pharmin-
gen, San Jose, CA, USA) was used for T-cell staining
and monoclonal anti-endothlin-1 (ED-1) antibody for
staining activated macrophages (Serotec, Oxford, UK).
Sections were mounted on glass slides coated with 2%
gelatin, deparaffinized, and rehydrated using standard
techniques. They were then exposed to microwave ir-
radiation in citrate buffer to enhance antigen retrieval.
Sections were incubated with avidin and biotin solu-
tions to block nonspecific binding of these compounds
(Blocking Kit) (Vector Laboratories, Burlingame, CA,
USA), followed by preincubation with 10% normal horse
serum to prevent nonspecific binding. Incubation with
the primary antibody was carried out overnight at 4◦C
in a humidified chamber. Negative control experiments
for all antigens were performed by omitting the incuba-
tion with the primary antibody. After washing, sections
were incubated with biotinylated antimouse IgG (Vec-
tor Laboratories) for 45 minutes. After rinsing, the re-
action product was detected with a strepavidin–alkaline
phosphatase complex (Vector Laboratories). The color
reaction was developed with diaminobenzidine (DAB)
substrate kit for peroxidase (Vector Laboratories) and
counterstained with hematoxylin. Quantification of T
cells and macrophages was performed in a blinded fash-
ion. The number of positively stained cells was counted
in 20 consecutive microscopic fields and the results were
expressed as a mean number of stained cells per mm2.
Systolic blood pressures were measured by the tail-cuff
method using a photoelectric sensor system (IITC Life
Science, Woodland Hills, CA, USA). The animals were
trained prior to the first measurement to remain calm in
a temperature-controlled restrainer. A mean of four to
six readings was recorded each time.
Results are expressed as mean ± SEM. Data on males
and females were analyzed both separately and com-
bined. Because there were no differences between the
sexes in any of the results (except body weights), only
the combined data are presented. Statistical comparisons
between two groups were performed by Student t test,
and between multiple groups by analysis of variance
(ANOVA) with Tukey’s post test or by Kruskal-Wallis
test with Dunn’s post test as appropriate. P value of <0.05
is considered statistically significant.
RESULTS
Series 1: Untreated offspring
As an index of tissue oxidative stress, kidney nitroty-
rosine content was determined by immunoblotting in
newborn rats and at the age of 4 weeks, immediately pre-
ceding the onset of hypertension in our model of prena-
tally programmed hypertension [8, 9]. The nitrotyrosine
content of newborn low protein diet kidneys was not sig-
nificantly different from that of newborn control kidneys,
but by 4 weeks the nitrotyrosine content of low protein
diet kidneys was increased by approximately 80% (Fig. 1).
As a potential source of increased reactive oxygen
species (ROS) production and tissue oxidative stress, kid-
ney content of T cells was assessed at 4 weeks of age.
Qualitative histology showed no obvious abnormalities,
but as shown in Figure 2, the number of CD3-positive
cells in low protein diet kidneys was markedly increased.
Twenty-four–hour urines were collected at 4 and
8 weeks of age for the determination of NOx excretion.
NOx excretion in the low protein diet offspring was signif-
icantly higher at 4 weeks than that of the control offspring
(Fig. 3A). At 8 weeks of age, the difference was no longer
statistically significant (Fig. 3B).
Series 2: MMF-treated offspring
Based on the hypothesis that infiltrating immune cells
contribute to the oxidative stress in the low protein diet
kidneys, the immunosuppressive drug MMF was used in
an attempt to reduce oxidative stress by preventing T-cell
and macrophage infiltration into the kidney. Control and
low protein diet rats were treated with MMF or vehicle
daily from age 3 to 6 weeks of age. MMF administra-
tion did not cause any obvious ill effects in the rats. Even
though the birth weights of the low protein diet pups were
significantly lower than those of the control pups (5.29 ±
0.13 g vs. 6.16 ± 0.10 g) (P < 0.0001), the difference disap-
peared by the beginning of the MMF treatment, and the
subsequent weights of the two MMF-treated groups did
not differ from those of the two vehicle-treated groups.
White blood cell count and hemoglobin was measured
Stewart et al: Renal inﬂammation in prenatally programmed hypertension 2183
2.5
2.0
1.5
1.0
0.5
0.0
N
itr
ot
yr
os
in
e,
 
re
la
tiv
e
 a
bu
n
da
nc
e
C LP
P = 0.027B
1.5
1.0
0.5
0.0
N
itr
ot
yr
os
in
e,
 
re
la
tiv
e
 a
bu
n
da
nc
e
C LP
P = NSA
Fig. 1. Tissue nitrotyrosine content. Kidneys from newborn (A) and
4-week-old (B) offspring from control (C) and low-protein (LP) preg-
nancies (N = 8 in each group).
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Fig. 2. CD3-positive cell count. Kidneys from 4-week-old offspring
from control (C) and low-protein (LP) pregnancies (N = 4 in each
group).
in animals killed at 8 weeks; there were no significant
differences between the groups.
Infiltration of the kidney by T cells and macrophages
was assessed at 8 weeks of age, 2 weeks after the
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Fig. 3. Urine NOx (nitrite + nitrate) excretion. Kidneys in 4-week-
old (A) and 8-week-old (B) offspring from control (C) and low-protein
(LP) pregnancies (N = 8 in each 4-week-old group) (N = 16 and 20 in
8-week-old control and LP groups, respectively).
completion of the MMF/vehicle treatment. As shown in
Figure 4, kidneys from untreated low protein diet an-
imals exhibited a markedly increased number of both
CD3-positive and ED-1–positive cells. MMF reduced the
CD3 cell content of the control kidneys but did not have
a significant effect on the number of ED-1 cells. MMF
treatment brought the number of both CD3 and ED-1–
positive cells in the low protein diet kidneys to the levels
observed in the untreated control group.
Kidney nitrotyrosine content at 8 weeks of age is il-
lustrated in Figure 5. MMF treatment had no significant
effect on the control kidneys. In contrast, it reduced the
nitrotyrosine content in the low protein diet kidneys to
the level of that in the control kidneys. MMF treatment
had a tendency to increase urine NOx excretion in both
control and low protein diet animals (Fig. 6).
Systolic blood pressure was determined at 8 and
10 weeks of age. As shown in Figure 7, MMF adminis-
tration did not alter the later blood pressure in control
rats. As expected, low protein diet rats were significantly
hypertensive at both time points compared with the con-
trol rats. MMF treatment appeared to totally prevent the
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Fig. 4. CD3 (A) and ED1 (B) positive cell count. Kidneys from 8-
week-old offspring from control (C) and low-protein (LP) pregnancies
treated with mycophenolate mofetil (MMF) or vehicle (V) from age 3
to 6 weeks (N = 4 in each group). ∗∗∗P < 0.001 compared with control-
vehicle group; +++P < 0.001 compared with low protein diet-vehicle
group.
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Fig. 5. Tissue nitrotyrosine content. Kidneys from 8-week-old off-
spring from control (C) and low-protein (LP) pregnancies treated with
mycophenolate mofetil (MMF) or vehicle (V) from age 3 to 6 weeks
(N = 8 in each group). ∗P < 0.05 compared with control-vehicle group;
+++P < 0.001 compared with low protein diet-vehicle group.
development of hypertension in the low protein diet rats
(Fig. 7).
Series 3: Tempol-treated offspring
To further explore the role of renal oxidative stress
in the pathogenesis of the hypertension, offspring pro-
grammed to become hypertensive as adults were treated
with the synthetic ROS scavenger Tempol for the 3-week
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Fig. 6. Urine NOx (nitrite + nitrate) excretion. Kidneys in 8-week-old
offspring from control (C) and low-protein (LP) pregnancies treated
with mycophenolate mofetil (MMF) or vehicle (V) from age 3 to 6 weeks
(N = 6 in control-vehicle group) (N = 11 in control-MMF group) (N
= 9 in low protein diet-vehicle group) (N = 8 in low protein diet-MMF
group). P = 0.026 by analysis of variance (ANOVA) (no significant
differences in Tukey’s post test).
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Fig. 7. Systolic blood pressure. Offspring from control (open circles
and squares) and low-protein (LP) (solid circles and squares) pregnan-
cies treated with vehicle (dashed lines) or mycophenolate mofetil (solid
lines) (N = 11–16 in each group). ∗∗P < 0.01 against all other groups.
period immediately preceding the onset of hypertension,
from 3 weeks to 6 weeks of age, and followed to 16 weeks
of age. The births weights of the low protein diet pups
were decreased as expected (5.10 ± 0.41 g vs. 6.12 ± 0.37g)
(P < 0.0001), but by the beginning of the Tempol treat-
ment the differences had disappeared, and there were no
significant differences between the groups at the end of
the observation period. Tempol caused no obvious side
effects in the treated animals.
The effect of Tempol treatment on kidney CD3-
positive cells at 8 weeks of age is shown in Figure 8. Again,
untreated low protein diet pups demonstrated a marked
increase in CD3 cells. Tempol treatment totally normal-
ized the CD3 count in low protein diet pups.
Kidney nitrotyrosine content at 8 weeks of age is illus-
trated in Figure 9. In this series, the difference between
control and untreated low protein diet groups did not
reach statistical significance. Tempol treatment resulted
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Fig. 8. CD3 positive cell count. Kidneys from 8-week-old untreated
offspring from control (C) and low-protein (LP) pregnancies and from
8-week-old low protein diet offspring treated with Tempol (LP-T) from
age 3 to 6 weeks (N = 4 in each group). ∗∗∗P < 0.001 compared with
control group; +++P < 0.001 compared with low protein diet group.
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Fig. 9. Tissue nitrotyrosine content. Kidneys from 8-week-old un-
treated offspring from control (C) and low-protein (LP) pregnancies
and from 8-week-old low protein diet offspring treated with Tempol
(LP-T) from age 3 to 6 weeks (N = 8 in each group). ∗P < 0.05 com-
pared with control group; +++P < 0.001 compared with low protein
diet group.
in marked decrease in the nitrotyrosine content in the low
protein diet rats to levels below those of the control rats.
Tempol treatment had no effect on urine NOx excretion
in the low protein diet rats (Fig. 10).
Figure 11 shows the blood pressure profile of the off-
spring from 8 weeks to 20 weeks of age. Short-term
Tempol treatment appeared to totally prevent the later
development of hypertension in low protein diet ani-
mals; throughout the observation period, from age 8 to
20 weeks, their systolic blood pressure were indistinguish-
able from those of the control rats.
DISCUSSION
The renal mechanisms participating in the generation
of prenatally programmed hypertension are incompletely
understood. The present study was designed to examine
the roles of two interdependent factors, immune cell infil-
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Fig. 10. Urine NOx (nitrite + nitrate) excretion. Kidneys in 8-week-
old offspring from untreated control (C) and low-protein (LP) preg-
nancies and from offspring treated with Tempol (LP-T) from age 3 to 6
weeks (N = 9 in control group) (N = 10 in low protein diet group) (N =
10 in low protein diet-Tempol group). P = 0.48 by analysis of variance
(ANOVA).
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Fig. 11. Systolic blood pressure. Offspring from control (open circles
and solid line) and untreated low protein (solid circles and solid line)
pregnancies and of low protein diet offspring treated with Tempol (solid
squares and dashed line) from age 3 to 6 weeks (N = 14 to 19 in each
group). ∗∗∗P < 0.0001 vs. all other groups.
tration and oxidative stress in the kidney. The results show
that prenatally programmed hypertension is associated
with immune cell infiltration in the kidney as determined
by immunohistochemistry, and with increased tissue ox-
idative stress as reflected by increased renal nitrotyrosine
content; both of these were present before the onset of
hypertension and can therefore not be considered con-
sequences of hypertensive injury. Remarkably, 3-week
treatment in early life with an immune cell-depleting
agent or with a superoxide dismutase mimetic prevented
the immune cell infiltration, reversed the nitrotyrosine
accumulation, and abolished the later development of
hypertension. These results strongly suggest that immune
cells and ROS are involved in the pathogenesis of prena-
tally programmed hypertension.
Although the presence of oxidative stress in hyperten-
sive individuals is well documented [33], it has been diffi-
cult to determine whether it plays a causal role in human
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hypertension. Recent experimental studies have, how-
ever, strongly supported the hypothesis that increased
oxidative stress does indeed cause hypertension [27].
Studies in the spontaneously hypertensive rat [34], in
the Dahl salt-sensitive rat [35], and in rat models of
acquired hypertension [30, 36, 37], have shown that
maneuvers designed to reduce oxidative stress such as
treatment with antioxidants or ROS scavengers ame-
liorate the hypertension. Conversely, inhibition of glu-
tathione synthase, which leads to increased oxidative
stress, induces hypertension in normal rats [38]. Impor-
tantly, oxidative stress in the kidney appears to be the
critical factor. The abundance of nitrosylated proteins,
considered a tissue “footprint” of oxidative stress, paral-
lels the appearance or resolution of hypertension in the
different models [24, 32, 38].
Our results on prenatally programmed hypertension
support the concept that renal oxidative stress may be
a common pathogenetic mechanism in all types of hy-
pertension. The fact that pharmacologic prevention of
oxidative stress by Tempol conferred a total normaliza-
tion of blood pressure to the low protein diet offspring
may reflect a central role of oxidative stress in prenatally
programmed hypertension; further studies are needed to
determine if, for instance, the metabolic pathways lead-
ing to ROS generation or ROS inactivation are targets of
programming in the fetus by maternal dietary deficiency.
Previous studies by others in nonrenal tissues support the
concept that maternal nutritional deficiency may lead to
a state of increased oxidative stress in the offspring [39].
There are at least two possible sources of ROS in the
kidney. There is good evidence that angiotensin II action
via the type 1 receptor increases oxidative stress by stimu-
lating nicotinamide adenine dinucleotide phosphate (re-
duced form) NAD(P)H oxidase in tissues, including the
kidney [24, 26, 28], and one previous study has suggested
that a similar mechanism may be operative in the mesen-
teric vasculature in prenatally programmed hypertension
[40]. Angiotensin II type 1 receptor is up-regulated in the
kidney before the development of hypertension induced
by maternal protein restriction [22, 23], and postnatal
treatment with an angiotensin-converting enzyme (ACE)
inhibitor prevents the development of hypertension de-
spite low circulating renin activity [41, 42], suggesting a
role for intrarenal RAS; the effect of MMF and Tempol in
the present study mirrored that of an ACE inhibitor given
over the same time period. These findings are consistent
with the hypothesis that activation RAS is responsible, in
part, for the increased oxidative stress within the kidney.
Another potential source of ROS in the kidney is in-
filtrating immune cells. Series of studies by Rodrı´guez-
Iturbe et al [30, 34, 43] have elegantly demonstrated that
in several other types of experimental hypertension, in-
filtrating immune cells create oxidative stress, and that
prevention of the cell infiltration both reduces the ox-
idative stress and ameliorates the hypertension. Similar
results have been obtained by others [44, 45]. Our results
not only show increased number of immune cells in the
kidney during the prehypertensive stage, but also that
treatment with MMF prevented the cell infiltration while
at the same time preventing or postponing the develop-
ment of hypertension. Thus, the present study suggests
that immune cell infiltration, although it may not be the
primary cause of oxidative stress, may contribute to the
sustained accumulation of ROS and thereby to the main-
tenance of hypertension.
The cause of the cell infiltration into the kidney in our
model is unknown. We have shown that qualitative histol-
ogy of the kidney early in the course is unremarkable [9].
However, Woods et al [10] have described subtle signs of
renal injury such as increased interstitial fibrosis in rats
programmed to become hypertensive as adults. Thus, it
is possible that subtle renal injury is present and is re-
sponsible for attracting immune cells into the kidney. Al-
ternately, accumulation of ROS, for instance as a result
of RAS activation as discussed above, may provide the
initial stimulus for attracting immune cells which would
then lead to further ROS production and a vicious cycle.
Our present results, showing the amelioration of cell infil-
tration by Tempol treatment, supports the latter concept.
Whatever the mediators leading to the inflammation and
oxidative stress, the primary programming event result-
ing from the mother’s nutritional deprivation must occur
in fetal life or during lactation. Because any postweaning
treatment of the offspring is unlikely to totally reverse
the primary abnormality, we were surprised at the sus-
tained effect of the MMF and Tempol after the treatments
were discontinued. However, the observation period is
not long enough to allow us to conclude that the devel-
opment of hypertension was permanently abolished.
Increased oxidative stress and inflammation in the kid-
ney may lead to hypertension by inducing inappropri-
ate sodium reabsorption [27]. A proposed mechanism is
through decreased nitric oxide bioavailability in the kid-
ney as a result of inactivation of nitric oxide by ROS [26,
27, 29]. Possible sites of action of decreased nitric oxide in-
clude the macula densa system [28, 46], the thick ascend-
ing limb of Henle [21, 47], and the collecting duct [48].
Our results, showing increased urine NOx excretion at
the prehypertensive stage, do not support the hypothesis
of limited nitric oxide bioavailability being important. In
contrast, we observed increased urine NOx excretion; this
may indicate activation of nitric oxide–mediated com-
pensatory mechanisms in response to ROS accumulation
and hypertension [49], similar to the finding in sponta-
neously hypertensive rats [50]. However, autocrine and
paracrine availability of nitric oxide within any nephron
segment may not be reflected in urine NOx excretion,
and the role of intrarenal nitric oxide therefore requires
further study.
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CONCLUSION
We have documented increased renal immune cell in-
filtration and tissue oxidative stress in a rat model of pre-
natally programmed hypertension, and shown that early
postnatal treatment designed to either prevent the im-
mune cell infiltration into the kidney or to directly reduce
the ROS burden in the kidney abolishes or postpones the
development of hypertension. The results support the hy-
pothesis that initial subtle renal injury leads to oxidative
stress and inflammatory response which promote renal
sodium retention and contribute to the development of
hypertension.
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